C
HRONIC MYELOID leukemia (CML) is a hematologic malignancy characterized by excessive clonal proliferation of myeloid cells and their progenitors. 1 It is typically associated with a reciprocal translocation between chromosome 9 and 22, t(9;22)(q34;q11), resulting in fusion of a central portion of the BCR gene to the second exon of the ABL gene. [2] [3] [4] [5] Although CML may have a prolonged course, it is generally a fatal disease with conventional therapy. Patients with CML undergoing allogeneic bone marrow transplant (BMT) from an HLA-identical sibling during the chronic phase have a 50% to 80% chance of long-term disease-free survival. [6] [7] [8] Much of the benefit of allogeneic BMT is mediated by an immune graft-versusleukemia effect. 8 The most direct evidence for this effect is the finding that donor lymphocyte infusions (DLI) can reinduce complete remission in approximately 70% of patients relapsing after BMT. Results of DLI are best when given early in the course of relapse. [9] [10] [11] [12] [13] [14] [15] Therefore, it becomes important to have a means of quantitative analysis for the low frequency of Philadelphia chromosome positive (Phϩ) cells in the marrow of such patients. Standard G-band cytogenetic analysis (CG) provides information on only a relatively small number of cells (Ͻ 25 metaphases) in such preparations, making the detection of a low frequency of Phϩ cells problematic. Polymerase chain reaction (PCR)-based molecular assays for BCR/ABL rearrangement are highly sensitive for the detection of Phϩ cells, and with quantitative methods, they may prove predictive for relapse, particularly in T-cell-depleted recipients. Some patients, however, may remain in durable complete remission despite persistently positive PCR results.
16, 17 We have combined fluorescence in situ hybridization (FISH) with long-term colcemid exposure of bone marrow cultures (called hypermetaphase FISH [HMF] ) and have shown it be effective in monitoring for the presence of specific chromosomal entities present in low frequency in leukemia patients undergoing treatment. 18 This approach is both sensitive and specific; up to 1,000 metaphases can routinely be studied, and the rate of false-positive readings is less than 2 ϫ 10
Ϫ4
. In this report, we applied the HMF technique to improve detection of early relapse after allogeneic BMT. HMF allowed the detection of low levels of Phϩ cells in 12 marrow transplant recipients who had not been found to have Phϩ disease by CG analysis performed simultaneously. The clinical significance of the HMF findings in those 12 patients was evaluated in an attempt to identify conditions when therapeutic intervention with DLI might be most effective in reestablishing complete remission.
PATIENTS AND METHODS

Patients
Fifty-one patients who received allogeneic BMT for CML at the University of Texas M.D. Anderson Cancer Center between January 1990 and September 1995 were the subject of this analysis. The transplantation protocols were approved by the M.D. Anderson Institutional Review Board. Samples were analyzed by HMF and separately by standard CG analyses. 19 The HMF assays were performed without knowledge of the patients' cytogenetic results or clinical status.
Transplant Regimen
Patients received either thiotepa (5 to 10 mg/kg), cyclophosphamide (120 mg/kg), and total-body irradiation (10.2 to 12 Gy) with CD8 or T-cell-depleted transplants [19] [20] [21] or thiotepa (750 mg/m 2 ), busulfan (12 mg/kg), and cyclophosphamide (120 mg/kg) and unmodified marrow transplantations. 20 
CG
CG analysis was performed on freshly aspirated bone marrow samples. Metaphases were analyzed for G-bands using trypsin-Giemsa techniques, as previously described. Twenty to 25 metaphases were analyzed. 19 
HMF
After a 24-hour culture of bone marrow aspirates followed by the addition of colcemid 1 g/mL and culture for an additional 24 hours for HMF preparation, 18 cells were fixed in acid-alcohol and dropped on slides by procedures standard in this laboratory. The E6B probe, from 5 million base pairs of human DNA spanning the breakpoint on chromosome 9q34 involved in the Ph translocation, was labeled with biotin for visualization with fluorescein for FISH detection of the Ph chromosome.
22 Digoxigenin-labeled alpha satellite DNA probe (Oncor, Gaithersberg, MD) for chromosome X, locus DXZ 1, was used for FISH identification (visualization with rhodamine) of donor cell versus recipient cells.
23 Two-color detection for each of the probes, fluorescent microscopy, and photography were carried out, as previously reported. 22 Criteria for evaluating Phϩ and PhϪ cells were as pub- 
RESULTS
Standard CG and HMF were carried out on all 51 patients at various time points after BMT. Four patients had high frequencies of Phϩ cells detected by both HMF and CG at all time points tested. Two subsequently died from their disease, and two have responded to DLI and have remained in complete remission for more than 2 years. Twelve patients were HMF-positive on initial determination without evidence of Phϩ cells by CG. The cytogenetic data (HMF and CG), intervention procedures carried out, and outcomes for the 12 patients are listed in Table 1 . The median time to cytogenetic progression (HMF Phϩ, CG PhϪ to HMF Phϩ, CG Phϩ) was 101 days. Low, but statistically significant, levels of Phϩ cells seen at first sampling in patients no. 9 and 10 did not necessarily have clinical significance; they have had negative HMF and CG studies. That these frequencies of Phϩ cells were detected seems to have been a likely consequence of the early time point after BMT (Ͻ 3 months). Detection of Phϩ cells by sensitive techniques within a few months after BMT has not had clinical significance in other studies as well, possibly because of the graft-versus-leukemia effect that is postulated to eradicate minimal residual disease after transplant. 16 Two of the patients (no. 5 and no. 6) died of therapy-related complications after being scored for less than 5% Phϩ cells less than 3 months after BMT and were not assessable for later relapse.
Clearly, HMF detects low frequencies of Phϩ cells not detected by CG. It is expected that, when the frequency of Phϩ cells is low, they might not be detected when only a 18 indicating that the false-positive readings in this procedure are less than 2 ϫ 10 Ϫ4 , the frequencies of Phϩ cells detected, with the exception of the positive readings in patient no. 11, are statistically significantly different from 0%.
Low percentages of Phϩ cells detected for the first time later than 3 months after BMT occurred in six patients (nos. 1, 2, 3, 4, 8, and 12) before they were detected by CG. These preceded clinical relapse as indicated by the subsequent readings and/or course of the disease in those patients. Acting on the information that low but significant levels of Phϩ cells present beyond 3 months after BMT may predict relapse, DLI was carried out on patient no. 7. 24 In that patient, low frequencies of Phϩ cells were detected by HMF 28 and 30 months after BMT. Also, over that same 2-month period, 274 to 328 recipient-derived female cells out of a sample of 400 cells (68% to 82%) were detected (Fig 1) .
Low frequencies of Phϩ cells were seen in patient no. 11 at two sample points 26 and 44 months after BMT. Patients may harbor Phϩ cells for years before relapse and continued monitoring is needed. Residual Phϩ cells may also be suppressed by the immune graft-versus-leukemia effect related to allogeneic transplantation, which may prevent overt relapse in these patients.
DISCUSSION
HMF Detection of Low but Statistically Significant Frequencies of Cancer Cells
Cytogenetic studies after allogeneic BMT for patients with Phϩ CML are of fundamental importance for documenting and monitoring the presence of residual malignant cells. Although some patients have only transient recurrence of Phϩ cells, Offit et al 25 reported on 16 CML patients in whom Phϩ cells were detected after transplant by standard cytogenetics; 12 of the patients experienced relapse (usually within 6 months in T-cell-depleted BMT recipients). Alimena et al 26 reported that the detection of Phϩ marrow cells at various intervals after BMT, even at low frequency (Ͻ 10%), was generally followed by a progressive increase of Phϩ cells and/or a hematologic relapse. Although cytogenetic analysis with G-banding is specific and reliable for detecting Phϩ cells, its sensitivity is limited by the relatively small number of cells analyzed in typical preparations (generally Յ 25 metaphases); hence, the statistical confidence in the measurement is low.
HMF identifies low frequencies of Phϩ cells not detected by CG because HMF allows evaluation of a much larger number of cells in each sample. For example, consider a hypothetical patient with a true level of 3% Phϩ cells. If we assume conservatively, based on the empirical evidence of zero Phϩ cells per 5,000 cells in samples from a known normal subject, 18 that the false-positive and false-negative rates each are less than 2 ϫ 10
Ϫ4
, then the probability of observing a given cell to be Phϩ in this patient is .0302. To decide whether this patient is Phϩ, formally, one tests the null hypothesis that the patient is normal, ie, has no Phϩ cells, versus the alternative that the patient has some Phϩ cells. Ideally, the overall false-positive and false-negative rates of the test should be controlled. For samples of n ϭ 25, n ϭ 400, or n ϭ 500 cells, rules that control the overall false-positive probability to be less than .0001 are to declare the patient Phϩ if (s)he has more than two Phϩ cells, more than two Phϩ cells, or more than three Phϩ cells, respectively. However, the false-negative probabilities of these rules, ie, the probabilities that a patient with 3% Phϩ cells is declared normal, are less than 0.01% for the n ϭ 400 and n ϭ 500 rules but 82.6% for the n ϭ 25 rule. That is, a sample of size n ϭ 25 cells, which is typical with CG, has a high risk of declaring a Phϩ patient normal. Changing the rule to more than one Phϩ cell out of 25 cells doesn't fix this problem because the false-positive rate becomes 0.5%, but the false-negative rate is 46.5%, still an unacceptably high risk of missing a true Phϩ level of 3%. If this type of rule is applied to patient no. 7 in Table 1 , (s)he would be declared Phϩ based on each of the first two samples (two Phϩ cells out of 400 cells and seven Phϩ cells out of 400 cells) but PhϪ based on each of the subsequent four samples, with a false-positive risk of 3.0% and a falsenegative risk of less than 0.0064%. A sample size of 25 cannot achieve anywhere near these levels of reliability.
Clinical Significance of Phϩ Cells Detected Early (3 months) After BMT
Disappearance of the Phϩ clone may occur in patients who had detectable cells early after transplant, presumably related to the graft-versus-leukemia effect. Consistent with this premise, detection of Phϩ metaphases generally predicts relapse after a T-cell-depleted or syngeneic transplant, presumably because of a lack of effective graft-versus-leukemia activity. As in patients no. 9 and no. 10, it is not unusual to see a low frequency of Phϩ cells within 3 months after BMT that are not detected subsequently. Similar results using HMF were reported by El-Rifai et al 21 on two patients.
Clinical Significance of Phϩ Cells Detected 3 Months or Later After BMT
In all seven cases where we found low but statistically significant levels of Phϩ cells by HMF that were not detectable by CG, the next cytogenetic readings (all within 6.5 months) indicated a higher percentage of Phϩ cells. These data are also supported in the study by El-Rifai et al, 21 in which two patients with significantly low levels (0.15%) of Phϩ cells, which were detected 4 months after BMT, relapsed. The level of Ph positivity that warrants therapeutic intervention is uncertain. In our study, patient no. 11 may be an example of a patient having less than a clinically significant level of Phϩ cells. In this patient, at 26 months after BMT, one cell in 500 was recorded as Phϩ. Although below our level of statistical significance, it is interesting to note that a second positive cell (out of 400 assayed) was recorded 18 months later (after two PhϪ readings in between), and close follow-up of this patient is warranted. Significantly low levels of Phϩ cells (Ͻ 0.30%) that have not resulted in relapse Phϩ readings 4 months later have also been reported for four patients by El-Rifai et al. 21 These data suggest that patients with less than 0.30% Phϩ cells detected by HMF (which would also be readily detected by PCR) may continue to sustain remission and may not require immediate intervention; however, close monitoring is still warranted.
When to Intervene?
Early recognition of CML relapse after BMT is becoming increasingly important with the recent documentation that DLI can reinduce complete remission via a graft-versusleukemia effect. This approach is most effective when applied early in the course of relapse. Kolb et al 13 reported that, among 84 patients, 14 patients (82%), 39 patients (78%), and one patient (12.5%) achieved complete remission after DLI for cytogenetic relapse, hematologic relapse, and transformed phase relapse, respectively. Similar data was reported by Collins et al. 15 Van Rhee et al 11 reported a higher remission rate and a lower risk of marrow aplasia and other complications in patients transplanted early in cytogenetic relapse rather than in overt hematologic relapse. Early intervention at a time in which donor-derived hematopoietic cells are dominant might prevent the complications associated with pancytopenia.
HMF can quantitatively assess early cytogenetic relapse. In our observations, seven of seven patients relapsed who had low levels of Phϩ cells (0.37% to 5.2%) detected by HMF and not by CG more than 3 months after BMT. Consistent with the concept that intervention is most efficacious given at a time of low burden of malignant cells, remission was induced by DLI in patient no. 7 who had 1.8% Phϩ cells 29 months after BMT. Firm conclusions on the indications for donor lymphocyte induction require further study in larger numbers of patients. This requires consideration of clinical factors as well as stage of disease at transplant, T-cell depletion, and histocompatibility relationships. However, the data presented suggests that the presence of 1% to 2% Phϩ cells by HMF at any single time point at least 3 months after BMT or progressively higher readings at least 3 months after BMT with at least 0.37% Phϩ cells may warrant intervention.
In conclusion, HMF provided a quantitative method to detect and observe the frequency of Phϩ cells after allogeneic BMT. The ability to score large numbers of cells provides statistical confidence regarding the frequency of malignant cells and may allow institution of DLI or other therapy early in the course of leukemia relapse at a time when intervention may be most effective. In future studies, it will be useful to apply the newer quantitative approaches to reverse transcriptase PCR 27 on the same samples analyzed by HMF to evaluate these different approaches for measuring clinically significant minimal residual disease.
